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Metabolic therapy involves the administration of a substance normally found in the human body to enhance cellular reactions 
involved in the pathogenesis of disease. Myocardial ischaemia/reperfusion injury represents a leading cause of morbidity and 
mortality, also in cardiovascular disease. Therapeutic strategies aimed at limiting cardiomyocyte death during the postischae-
mic reperfusion and in the perioperative settings are nowadays extensively studied. Conceived originally as a dietary constitu-
ent (known as vitamin B13) only, it is now apparent that most orotic acid is synthesized in the human body where it arises as 
an intermediate in the biosynthetic pathway of pyrimidine nucleotides. Previous investigations in the heart suggest that orotate 
and its derivatives could be of significant clinical benefit in the treatment of heart disease. The present brief review is concerned 
with the current knowledge of the major effects of these compounds in both experimental and clinical cardiology. The potential 
mechanisms and biochemical pathways responsible for cardioprotection are highlighted. Biomed Rev 2010; 21: 47-55.
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INTRODUCTION
Myocardial ischaemia/reperfusion injury represents a major 
cause of morbidity and mortality worldwide being associ-
ated with acute coronary syndromes, particularly acute myo-
cardial infarction that has been predicted to become by the 
year 2020 the first cause of death in the world (1). Timely 
coronary reperfusion by either thrombolysis or primary coro-
nary artery angioplasty has become the established routine 
therapy that effectively decreases infarct size and reduces 
mortality. Despite the unequivocal beneficial effects in stop-
ping the progression of irreversible damage, reperfusion per 
se is considered a double-edged sword (2) as it can induce 
severe myocardial lesions, known as lethal reperfusion in-
jury that paradoxically may alleviate the beneficial effects of 
revascularization (3). Moreover, there is no clinically avail-
able therapeutic intervention able to reduce infarct size in as-
sociation with the revascularization procedures. Accordingly, 
cardioprotection, defined as the totality of pharmacological 
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and mechanical interventions aimed at reducing cell death 
during/after myocardial ischaemia/reperfusion, continues to 
be the focus of considerable research effort for both under-
standing the underlying mechanisms (4) and translating the 
experimental findings into clinical therapy (5,6).
  This article attempts to summarize the present state of 
knowledge of cardioprotective potentials of orotate-based 
metabolic therapy in both experimental and clinical settings.
BIOCHEMISTRY OF OROTIC ACID
Orotic acid is a natural substance present in high concentra-
tion in dairy products (oros means “whey” in Greek) classi-
fied more than 40 years ago as vitamin B13 and mainly used 
in the past for the treatment of pernicious anaemia. Its major 
metabolic role within the human body consists of that it is 
the first fully formed intermediate in the manufacture of the 
pyrimidine bases (7) required for the RNA/DNA synthesis. 
In the de novo pathway of pyrimidines biosynthesis, the en-
zyme orotate phosphoribosyltransferase (OPRTase), found in 
organisms ranging from yeast to humans, catalyzes the for-
mation of orotidine 5’-monophosphate (OMP) from orotic 
acid and 5-phosphoribosyl-1-pyrophosphate (PRPP) which 
in turn is further used as a substrate for uridine nucleotides: 
uridine monophosphate (UMP) and uridine triphosphate 
(UTP) synthesis (Fig. 1). Because the enzyme OPRTase 
requires magnesium ions for its activity, early studies sug-
gested that the true substrate for OPRTase is not orotate it-
self, but rather a magnesium-orotate complex (8). These re-
searchers hypothesized that the magnesium complex helps 
position orotate within the enzyme in the proper orientation 
for conversion to OMP. In contrast, some of the mineral oro-
tates such as copper and nickel either inhibit OPRTase or, in 
the case of calcium orotate, neither activates nor inhibits the 
enzyme activity. However, subsequent work of Bhatia and 
Grubmeyer (9) infirmed this hypothesis by showing that, at 
least in yeast, the role of divalent metal must be to bind PRPP, 
because orotate-metal complex is not necessary for OPRTase 
catalysis and only weak metal-enzyme complexes may form 
in bacterial OPRTase. UTP thus synthesized can be further 
utilized for the synthesis of cytidine triphosphate (CTP): the 
amino group of CTP is donated from glutamine in an ATP-
dependent reaction catalyzed by CTP synthase (Fig. 1). 
  Uridine nucleotides are also the precursors for de novo 
synthesis of the thymine nucleotides: this pathway requires 
the use of dUMP which is converted to dTMP by the ac-
tion of thymidylate synthase. The methyl group (thymine is 
5-methyl uracil) is donated by tetrahydrofolate (similarly to 
the donation of methyl groups during the biosynthesis of the 
purines). 
  Besides this energetically expensive, multistep de novo 
pathway, the pyrimidine nucleotide pools are sustained by 
the recycling of the basic components derived from their ca-
tabolism during the normal process of cell turnover, the so-
called “salvage”, PRPP independent pathway. 
  Uracil can be “salvaged” to form UMP through the con-
certed action of uridine phosphorylase and uridine kinase, as 
indicated below: 
uracil + ribose-1-phosphate  uridine + Pi 
uridine + ATP  UMP + ADP
Deoxyuridine is also a substrate for uridine phosphorylase. 
Formation of dTMP, by salvage of dTMP requires thymine 
phosphorylase and thymidine kinase: 
thymine + deoxyribose-1-phosphate  thymidine + Pi 
thymidine + ATP  dTMP + ADP
Thymidine kinase can also use deoxyuridine as substrate: 
deoxyuridine + ATP  dUMP + ADP
The activity of thymidine kinase (one of the various deoxyri-
bonucleotide kinases) is unique in that it fluctuates with the 
cell cycle, rising to peak activity during the phase of DNA 
synthesis; it is inhibited by dTTP.
The salvage of deoxycytidine is catalyzed by deoxycytidine 
kinase: 
deoxycytidine + ATP  dCMP + ADP
The major function of the pyrimidine nucleoside kinases is to 
maintain a cellular balance between the level of pyrimidine 
nucleosides and pyrimidine nucleoside monophosphates. 
However, since the overall cellular and plasma concentra-
tions of the pyrimidine nucleosides (as well as those of ri-
bose-1-phosphate) are low, the “salvage” of pyrimidines by 
these kinases is relatively inefficient. 
EXPERIMENTAL EVIDENCE 
Experimental evidence with OA can be traced back to the late 
60s when a Russian physiologist, E.Z. Meerson, demonstrat-
ed for the first time the cardioprotective effect of OA admin-
istration during his pioneering studies on experimental hyper-
trophy induced by aortic ligation in rabbits. In this respect, he 
described the first stage of acute hypertrophy, known as the 
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Figure 1. De novo Biosynthesis of Pyrimidine Nucleotides.
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‘emergency’ or ‘damage’ stage, as being characterized by the 
impairment of contractility together with an acute increase in 
protein synthetic rates and considered the latter as the major 
responsible for the structural adaptive changes of myofibrils 
enabling the heart to undergo transition to the second stage of 
‘stable compensation’ which was allowing a better contrac-
tion (10,11). In this same vein, Meerson postulated the ‘rela-
tive deficiency theory’, i.e., the deficiency of cofactors such 
as OA as being responsible for the limitation of the extent of 
protein and nucleic acids synthesis activation during hyper-
trophy. Administration of potassium orotate, as a precursor 
of RNA synthesis, for the first 4 days after the aortic liga-
tion, enhanced the rate of protein synthesis, improved con-
tractility and almost completely prevented the appearance 
of acute heart failure (12). These investigators further con-
firmed the beneficial effects of chronic orotate administration 
post-experimental myocardial infarction in rats (13) and they 
postulated as putative mechanism, the prevention of drop in 
cathecolamines concentration in the non-ischaemic zone of 
the myocardium (14). 
  The first Western author who confirmed the protective 
role of OA in the experimental setting was an Australian bio-
chemist, J.F. Williams. His seminal studies (reviewed in 15) 
on the biochemistry and functional role of OA in the acute 
hypertrophying rat heart provided extensive evidence con-
cerning the major metabolic pathways activated by chronic 
treatment with OA (10 mg/kg/day started immediately af-
ter the induction of hypertrophy). The proposed inter-organ 
connections of these metabolic activations thought to be re-
sponsible for the enhancement of contractility and functional 
performance improvement during the first four days of de-
veloping cardiac hypertrophy in rat are summarized in Figure 
2. The orotate-related cardioprotection can be attributed to 
the following mechanisms: (i) stimulation of the pyrimidine 
synthesis in liver via the PRPP independent salvage pathway 
followed by the transport of the bases (mostly as uridine) to 
the heart where their conversion to nucleotides will be per-
formed (with a subsequent increase in the RNA synthesis rate 
within the heart); (ii) enhancement of the myocardial glyco-
gen stores due to the high levels of uridine and UDP-glucose 
in the heart coupled with a higher flux in cardiac glycolysis 
with two consequences: (a) the expansion of the glycolytic 
intermediates concentration, and (b) the preservation of the 
cytoplasmic NAD+/NADH ratio in the physiological range, 
(iii) the elevated levels of glucose-6-P and fructose-6-P can 
force glycolytic intermediates to entry into the non-oxidative 
reaction segment of the pentose pathway. As a consequence, 
the activation of ribose-5-P formation via reversal of the L-
type pentose pathway in the heart will increase the PRPP 
generation whose concentration regulates both de novo and 
the salvage pathways for adenine nucleotide synthesis; the 
subsequent augmentation of adenylates (AMP, ADP) con-
centration will further increase the ATP availability, and (iv) 
the predominant use of the pyrimidine salvage pathway in 
the heart together with the enhanced production of pyrimi-
dine bases in organs distant from the heart spares myocardial 
PRPP for the more dominant de novo adenine nucleotide syn-
thesis (16). These latter authors demonstrated the ability of 
OA treatment to “energize” cardiomyocytes evaluated by the 
phosphorylation state of the adenine nucleotides, a parameter 
that is considered the best predictive index of the cellular en-
ergy status in normal and hypertrophying hearts (17).
  The beneficial effects of orotate on the cardiac function 
were further reproduced by Williams’ group in infarcted 
working rat hearts exposed to a 60 minutes period of hy-
pothermic cardioplegic arrest (18,19). These investigators 
demonstrated that: (i) regardless the protective effect of hy-
pothermic cardioplegia, a rather small-sized left ventricular 
myocardial infarction induced a marked reduction of the 
ability of the heart to recover from global ischaemia, and (ii) 
pretreatment with OA produced a substantial improvement of 
infarcted hearts. The same research team reported the lack of 
a direct effect of OA on cardiac function in normal isolated 
working rat hearts in both acute and chronic administration. 
Protection elicited by orotate in this setting was ascribed 
to the same mechanisms described for the hypertrophying 
hearts, namely: (i) the high rate of protein synthesis in non-
infarcted myocardium with the putative restoration of the 
metabolic enzymes in the surviving areas that might allow a 
better recovery from ischaemia, (ii) enhancement of the myo-
cardial glycogen stores (via increasing the UDP-glucose lev-
els) that will supply the substrate for anaerobic metabolism 
during ischaemia, (iii) augmentation of phospholipids bio-
synthesis (via increased cytidine nucleotide production) will 
allow the repair of the ischaemia induced membrane damage, 
and (iv) prevention of adenine nucleotides depletion in the 
surviving myocardium together with the subsequent increase 
in the ATP availability will allow a better recovery post-glo-
bal ischaemia (17,20). The observation that orotic acid im-
proves cardiac performance of the ischaemic/reperfused rat 
hearts via the elevation of myocardial glycogen content was 
further confirmed (21).
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Figure. 2 Possible Metabolic Pathways Activated by Orotic Acid
(UTP = uridine triphosphate, CTP = cytidine triphosphate, PRPP = 5-phosphoribosyl-1-pyrophosphate)
  The salts of OA have been also shown to exert protective 
effects on cardio-vascular system in both experimental and 
clinical studies, albeit the mechanisms of protection are not 
entirely elucidated. Thus, Bajusz et al (22) demonstrated the 
beneficial effect of potassium orotate in preventing the de-
velopment of the dystrophic Syrian hamster cardiomyopa-
thy, a chronic heart disease associated with skeletal muscle 
dystrophy. The authors attributed it initially to the effect of 
potassium (as these animals were extremely sensitive to hy-
pokaliemia). However, it was shown that sodium orotate was 
equally effective in improving myocardial contractility, sug-
gesting that the beneficial effect should be ascribed to OA 
(23). These latter authors revealed that OA, in chronic ad-
ministration, was able to restore the sialyltransferase activity 
to the normal levels; this sarcolemmal enzyme is responsible 
for the sialic acid incorporation into the interstitial glycopro-
teins involved in the excitation-contraction coupling process. 
Sialic acid is the terminal monosaccharide within the mem-
brane glycoproteins with at least two major roles in mamma-
lian myocardium: as binding sites for the calcium involved in 
excitation-contraction coupling, also regulator of membrane 
permeability to calcium ions. 
  More recently, Jasmin et al (24) confirmed the superior-
ity of chronic treatments (30 and 50 days, respectively) with 
magnesium orotate as compared to orotic acid in reducing 
the myocardial degeneration (especially the severity of calci-
fications) and the development of congestive heart failure in 
cardiomyopathic hamsters with a similar efficiency for both 
compounds in prolonging their survival. Similarly, Jellinek 
and Takacs (25) reported a beneficial effect of magnesium 
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orotate that performed better than OA which in turn outper-
formed magnesium chloride in preventing the development 
of atherosclerotic lesions in rabbits chronically fed with an 
enriched cholesterol diet. These authors also speculated on 
possible mechanism underlying this effect: they suggested 
that OA in the magnesium orotate complex might become 
coupled with ribose (ribosylated) in the walls of blood ves-
sels and the subsequent release of magnesium during this 
process will render the ions locally available for activating 
cholesterol-metabolizing enzymes.
  At variance from its beneficial effects in chronic admin-
istration, we have investigated the cardioprotective effect of 
magnesium orotate in acute administration during the reper-
fusion post-global ischemia in isolated perfused rat hearts 
(26). In this study, the postischaemic recovery of contractile 
function was assessed and the effects of MO (1 mM) were 
compared to the ones elicited by cyclosporine A (0.2 μM), 
a recognized cardioprotective agent at mitochondrial level 
(27). 
  We reported a comparable degree of protection on contrac-
tile function for both magnesium orotate and cyclosporine A 
in isolated heart subjected to 30 min of global ischemia and 2 
hours of reperfusion (Fig. 3). 
  In order to identify the major agent responsible for car-
dioprotection at reperfusion we have compared the effects 
of magnesium orotate on postischemic recovery of contrac-
tile function and infarct size with the ones elicited by an 
equivalent dose of OA and magnesium chloride, respectively 
(unpublished results). Our preliminary data show that, when 
Figure 3. Postischemic recovery of contractile function in isolated rat hearts (percentage of their pre-ischemic value).  
LVDP = left ventricular developed function. Mg-O = magnesium orotate, CsA = cyclosporine A (p < 0.001 Mg-O and CsA vs. 
Control)
given at reperfusion, magnesium orotate was associated with 
a better cardioprotective effect when compared to OA (sug-
gesting that a synergy might exist between magnesium and 
OA) whereas magnesium chloride administration had no 
beneficial effects. Current investigations are ongoing in or-
der to identify the mechanisms underlying acute cardiopro-
tection related to magnesium orotate administration at reper-
fusion with a possible contribution of mitochondria.
CLINICAL EVIDENCE
Orotate (in form of potassium salt, 500 mg t.i.d) was initially 
used during in the early 1970s in cardiovascular patients in 
the former Soviet Union and in Bulgaria, but comprehensive 
information available in English concerning this early experi-
ence was rather limited (28). In 1991, Rosenfeldt (29) briefly 
reviewed during an international symposium the clinical tri-
als reported in the Russian literature, showing that potassium 
orotate was effective when added to standard therapy, mainly 
in 2 major settings: acute myocardial infarction (30-32) and 
severe heart failure (33). In the case of the former indication, 
some authors underlined the importance of early administra-
tion, reporting that giving orotate in the first 1-3 days after 
infarction was followed by a reduction in the incidence of 
cardiac complications as compared with patients starting 
therapy after 4-7 days. All these studies, even if including 
a small number of patients, showed a quicker restoration of 
myocardial contractile function, a lower incidence of early 
arrhythmic complications and a decreased mortality rate after 
myocardial infarction in patients receiving orotate together 
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with the conventional therapy. The same beneficial effects to-
gether with a clinical improvement and less digoxin toxicity 
were reported in the case of chronic treatment with orotate in 
patients with heart failure (33). Moreover, the treatment with 
OA and its salts was further extended to other heart diseases 
such as severe angina (34), rheumatic myocarditis (35) and 
mitral valve disease (36). Surprisingly - or, as often happened 
in science - for the next almost two decades, these studies 
with few exceptions (37,38) have been neglected. 
  Recently, Stepura and Martynow (39) reported the benefi-
cial effects of adjuvant magnesium orotate on clinical symp-
tomatology, survival rate and quality of life in patients with 
severe heart failure under optimal cardiovascular medication. 
In line with the “upregulation” of scientific interest to orotate 
and its derivatives, recent studies provided experimental evi-
dence for their cardioprotective significance, including anti-
necrotic and anti-arrhythmic effects (40-42, cf. 43,44). How-
ever, the precise mechanism by which orotate combinations 
are more effective than OA alone remains still elusive in the 
metabolic therapy of cardiovascular diseases (45).
CONCLUSION
We have highlighted the cardioprotective effects caused by 
OA and/or its derivatives. A better understanding of the com-
plex mechanisms responsible for these effects may further 
widen the therapeutic potential of such a simple and safe 
metabolic therapy. In future, possible implications of OA 
and/or its derivatives in the pathogenesis and therapy of cer-
tain cardiometabolic diseases such as atherosclerosis (25), 
type 2 diabеtes and the metabolic syndrome might represent 
a novel research field to be pursued. 
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